Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Lomustine-temozolomide vs. temozolomide bij glioblastoom met gemethyleerde MGMT-promotor
mrt 2019 | Neuro-oncologie